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Abstract
Recent highly expected structural characterizations of agonist-bound and antagonist-bound beta-2
adrenoreceptor (β2AR) by X-ray crystallography have been widely regarded as critical advances
to enable more effective structure-based discovery of GPCRs ligands. It appears that this very
important development may have undermined many previous efforts to develop 3D theoretical
models of GPCRs. To address this question directly we have compared several historical β2AR
models versus the inactive state and nanobody-stabilized active state of β2AR crystal structures in
terms of their structural similarity and effectiveness of use in virtual screening for β2AR specific
agonists and antagonists. Theoretical models, incluing both homology and de novo types, were
collected from five different groups who have published extensively in the field of GPCRs
modeling; all models were built before X-ray structures became available. In general, β2AR
theoretical models differ significantly from the crystal structure in terms of TMH definition and
the global packing. Nevertheless, surprisingly, several models afforded hit rates resulting from
virtual screening of large chemical library enriched by known β2AR ligands that exceeded those
using X-ray structures; the hit rates were particularly higher for agonists. Furthemore, the
screening performance of models is associated with local structural quality such as the RMSDs for
binding pocket residues and the ability to capture accurately most if not all critical protein/ligand
interactions. These results suggest that carefully built models of GPCRs could capture critical
chemical and structural features of the binding pocket thus may be even more useful for practical
structure-based drug discovery than X-ray structures.
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Structure based drug discovery (SBDD) has become a major strategy in identifying novel
leads for important biological targets. SBDD enabled well documented discovery of several
approved drugs, e.g. dorzolamide and imatinib. Typically, the 3D structures of biomolecules
obtained by the means of X-ray crystallography and NMR spectroscopy are needed for the
purpose of virtual screening (VS), whose performance is strongly affected by the quality of
biomolecular structure, especially with respect to binding site description. When no
experimentally determined structures are available, theoretical models based on either
homology(comparative) or de novo modeling approaches are employed instead17, 21, 34.
However, there were some debates about the accuracy and applicability of theoretical
models10, 11, 20, 28, 30, 40 in SBDD. In principle, the success of theoretical modeling is
typically measured by how close the models could reproduce experimental structures, which
implies that the latter are regarded as inherently more appropriate choice for SBDD
applications.
G-protein coupled receptors (GPCRs) is a protein family where theoretical models have
been used widely because of GPCRs’ importance as targets for many drugs, on one hand,
and the lack of experimental structures, until recently, on the other hand. The experimental
effort to characterize the 3D structure of GPCRs had been seriously hindered by membrane
related issues8. A large number of theoretical models have been employed in the past
decades22, 24, 35, 47, 54, 59, 64 for VS often yielding reasonable results7, 12, 18, 19, 33. However,
it was fully expected that the availability of the experimental structure of any GPCRs would
substantially enhance the efficacy of SBDD efforts. Thus, the recent characterizations of the
crystal structures of human beta-2 adrenergic GPCR (β2AR) in both agonist-bound49, 52 and
antagonist-bound states13, 50, 51, cleared the way for the validation of previous theoretical
models, as well as provided critical data for building homology based models of other
GPCRs as the most obvious structural template.
It has been shown that human β2AR features a structurally conserved rhodopsin-like 7TM
core, but there exist novel structural features that had not been identified previously. It
remained unclear as to whether these structural divergences would affect the outcome of VS
studies. Dissimilarity of theoretical models relative to the crystal structure should lead to
relatively poorer performance of the former in docking and scoring of known ligands;
however, this general expectation should not necessarily be regarded as a law. One should
take into account that some of the theoretical models are actually manually refined with
known medicinal chemistry data and therefore, there is at least a possibility that theoretical
models may be even more suitable for drug discovery by VS than the crystal structure.
In this study, we have addressed this, both scientifically and pragmatically, important
question directly. We have compared the X-ray structure of β2AR vs. several previously
built theoretical models in terms of their respective ability to recover known β2AR ligands
(both agonists and antagonists) from a large external compound library in VS experiments.
None of these models were generated in our group to ensure objective and unbiased
comparisons. Furthermore, although our group has developed both scoring functions63 and
virtual screening protocols44, for the same reasons we restricted ourselves to using several
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popular commercial docking and scoring tools developed elsewhere. Thus, by design, this
study lacked any user biases concerning preferred theoretical models or most familiar
computational tools to emulate the situation that is most commonly faced by the majority of
molecular modeling practitioners both in academia and industry.
There have been previous studies on comparing homology models among themselves or
even with the crystal structure but to the best of our knowledge nobody approached the
question poised herein as retrospectively and broadly as we did. For instance, Bissantz et al
employed three human GPCRs models derived from rhodopsin for virtual screening using
multiple docking programs and scoring functions10. Their work proved that homology
models are suitable for VS but there was no comparison to the crystal structure. After the
crystal structure of human β2AR was published, Costanzi reported two studies where
carazolol was docked both into two rhodopsin-based homology models of human β2AR as
well as into its X-ray structure of inactive state16, 57. The models afforded high accuracy of
the docking poses and ideal enrichment for both antagonists and agonist, especially after
incorporating the biochemical data to adjust the orientation of the binding pocket residues.
However, these studies were limited to their in-house models and lacked of global structural
comparison. More recently, Fan et al reported that for 27 out of the 38 protein targets, the
consensus enrichment for multiple homology models was better than or comparable to that
of both the holo- and the apo- X-ray structures20. However, that study was focused on
soluble protein targets and applied a single homology model building tool that employed X-
ray characterized structural templates. In contrast, all models included herein were built
before the β2AR crystal structures became available as possible templates. Michino et al.
and Kufareva et al. recently reported two large-scale assessments of current GPCR modeling
efforts and molecular docking capacities37, 41. While their studies provided important
insights on how to improve current structure prediction and docking techniques to reproduce
the X-ray structures, our studies focus primarily on the pragmatic question as to whether
computational models of GPCRs how they could be used successfully for structure based
drug discovery.
We have carried out a systematic, retrospective study on a large collection of published
human β2AR theoretical models and evaluated their structural accuracies and virtual
screening performances in comparison with three crystal structures, i.e., 2RH1 (released by
the RCSB Protein Data Bank (PDB) on Oct. 30, 200713), 3D4S (released by RCSB PDB on
Jun. 17, 200826), and the latest agonist-bound structure 3P0G (released by RCSB PDB on
Jan. 19, 201149). Two other structures, 2R4R and 2R4S50, were not employed because they
came from the same source as 2RH1 but with lower resolutions. Another agonist-bound b2
adrenoceptor structure, 3PDS with an irreversible disulfide bond between ligand and
complex, was not used because its conformation is more close to the inactive state52. As
shown in Table I, we collected eight independently published theoretical models of human
β2AR including both apo and holo structures. Both agonist and antagonist bound models
were included to account for any structural features associated with functional activity.
Furthermore, we incorporated both homology and de novo models to cover these two major
types of GPCRs modeling.
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Surprisingly, we found that some of the theoretical models displayed better or comparable
VS performances than the crystallographic structures. This study by no means undermines
the extreme significance of the X-ray structures of β2AR as well as other
GPCRs13, 29, 45, 46, 60, 62 in understanding the intricate details of GPCRs structure in relation
to its function nor in the significance of X-ray structures for SBDD. Nevertheless, it most
certainly testifies to the importance of intelligent computational modeling approaches
especially those incorporating comprehensive medicinal chemistry knowledge of receptor/
ligand complex for structure based virtual screening.
Materials and Methods
Structural similarity analysis
In addition to crystal structures of inactive state (PDB ID: 2RH1) and active state (PDB ID:
3P0G) of human β2AR, the structure of bovine rhodopsin (PDB ID: 1U19) in dark state was
also included in the analysis because it had been used as the major template for all β2AR
homology models. The structural similarity was assessed in three aspects, i.e. the accuracy
of the boundary definitions for each transmembrane (TM) helixes, the backbone root-mean-
square-deviation (RMSD) for TM regions, and the Cα RMSD of the binding pocket
residues. The numbering of amino acids followed the conventions set by Weinstein et al58.
The highly conserved residues embedded in each TM region were employed as anchors for
the alignment. Each theoretical model was structurally aligned against 2RH1, 3P0G or 1U19
by individual TM helix as well as the whole TM bundle. The RMSDs were calculated using
the entire lengths of the corresponding segments of 2RH1.
Screening libraries
Active seeds—To include most known binders, we collected 57 known antagonists of
human β2AR reported in DrugBank61 and GLIDA43 databases as active seeds. All
antagonists have sub-micromolar potency and can be found in additional external databases,
such as PDSP Ki53, PubChem5 and KEGG31. A few of them are β2AR specific (e.g.
butoxamine and aminoflisopolol) while others can act on both β1AR and β2AR. In the
meantime, we compiled the agonist set of thirteen full agonists for human β2AR from the
DrugBank database.
Decoys set I: PDSP binding decoys plus WDI drug-like decoys—As our initial
effort to establish a reasonable decoy dataset for virtual screening, we employed the World
Drug Index (WDI) database version 20041 since most of its compounds are drug-like. The
original collection of 59,000 molecules was first cleaned by removing metals, salts and
fragments, then filtered to eliminate unqualified compounds according to Lipinski’s rule of
five and later extensions of this rule25. The remaining collection of ca. 38,000 compounds
was further reduced to a diverse subset of 374 compounds using MOE2007.09. In addition,
12 binding decoys with similar chemical scaffolds but poor binding affinity (Ki > 10μM)
were selected from the PDSP Ki database and merged into the WDI diverse subset. In the
end, 57 human β2AR antagonists and 13 agonists were seeded amongst 386 decoys
separately to constitute two different screening libraries.
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Decoys set II: ChEMBL binding decoys plus Schrodinger drug-like decoys—In
an effort to avoid the bias brought by one single screening library, we built another decoys
set which includes 1000 drug-like decoys23 from Schrodinger web portal and 916 known
nonbinders from ChEMBL database (https://www.ebi.ac.uk/chembl/). The size of this
decoys set is fairly large and the ratio of actives to decoys is (r=33.6 for β2AR antagonists)
close to the criteria set by the DUD database (r=36.0). The ChEMBL binding decoys were
selected based on the standards similar to the ones in the decoys set I for PDSP database but
of large number.
Decoys set III: Subset of II containing N+ only—Like other amine GPCRs families,
β2AR’s ligands are special in that they normally contain a positively charged nitrogen at the
side chain portion, which is a key ingredient of the binding event. To ensure that the power
of current scoring function is based upon factors other than this simple structural feature, we
created the 3rd decoys set by applying this filter (N+ present) to the decoys set II. In the end,
there were 652 compounds left with positively charged nitrogen.
Molecular docking methods
We employed three popular docking programs, i.e. Glide4.01, AutoDock4.0 and eHiTS6.2,
to evaluate systematically the screening performance of structural models.
Glide4.01—The calculations by Glide version 4.0123 was carried out using Schrodinger
Suite 2007. The targeted protein and theoretical models were prepared through Protein
Preparation module with the default setting and assigned with the OPLS 2001 force field
atom types and partial charges. The screening databases were prepared within the LigPrep
module and the ionization states of each molecule were calculated as to be compatible with
the pH value of 7.0±2.0. All molecules were subjected to energy minimization with MMFFs
force field before the docking computation. For X-ray structure and holo models, the center
of the grid box was selected as the center of bound ligands. For apo models, their binding
pockets were first aligned to that of 2RH1 and the center of co-crystallized carazolol was
chosen. The proper size of the enclosing box was not set to be fixed but determined by the
extent of the bound ligand. The Glide SP scoring function was used to rank the docking
poses and the top-ranked poses for each database molecule were saved for post-docking
analysis.
AutoDock4.0—We prepared the targeted protein and docking parameters for AutoDock
version 4.027, 42 using the AutoDockTools graphic interface. Explicit hydrogen atoms were
added to the receptor structures while atom types and partial charges were assigned to
generate the pdbqt receptor files. The database molecules were prepared using the
‘prepare_ligand4.py’ script to merge non-polar hydrogen atoms and define flexible torsions.
The center and dimension of the enclosing boxes were defined to include the whole binding
pockets, similar to those in the Glide docking. The genetic algorithm were employed during
the docking with a start population size of 150 individuals and 20 runs combined with a
maximum number of 12,500,000 energy evaluation for each molecule. Other parameters for
genetic algorithm were kept by the default value.
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eHiTS6.2—The eHiTS version 6.265 was used through the CheVi user interface. Protein
preparations, such as protonation state determination for residues, hydrogen atoms addition
and partial charge assignment, were actually not needed since eHiTS’ docking and scoring
are based on the prior training data of its knowledge base of 97 protein families. The grid
box was assigned automatically using the bound ligand’s SDF file as the CLIP file. We
employed the default settings for eHiTS docking and ranked the database molecule based on
its lowest eHiTS score.
In addition, we added eight more scoring functions of different types by rescoring the top-
ranked poses generated by Glide4.01, to ensure an unbiased and complete comparison. The
multiple scoring functions in Sybyl8.04 CScore module and OpenEye2 FRED 2.2.4 were
applied, including Chemscore, D_score, Gold_score, PMF, Chemgauss3, PLP, Screenscore
and Shapegauss. The consensus scores were also used for the above scoring functions
through the rank by rank strategy.
Assessment of virtual screening performance
To measure the efficiency of virtual screening we used the following conventional
parameters: the enrichment factor and the receiver operating characteristic (ROC) curve that
characterizes the ability if a method to recover known ligands among the top-scored
screening molecules. The enrichment factor follows the most popular definition as to how
many more seed compounds (i.e., known ligands) were found within a defined “early
recognition” fraction of the ranked list relative to a random distribution:
(1)
where Hscr is the number of target-specific seeds recovered at a specific % level of the
database; Htot is the total number of seeds for the target; Dscr is the number of compounds
screened at a specific % level of the database; Dtot is the total number of compounds of the
database. The ROC curve is generated by plotting the sensitivity (Se) vs. (1 – specificity
(Sp)) for a binary classifier system as its discrimination threshold is varied. In the case of
virtual screening for recovering the ith known active from the inactive decoys, the Sei and
Spi are defined as follows:
(2)
(3)
The area under the ROC curve (AUC) is the metric that is widely accepted for assessing the
likelihood that a screening method assigns a higher rank to known actives than to inactive
compounds. The AUC values at a specific percentage of the ranked database are calculated
from the following equation:
(4)
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Here n is the total number of known actives in the screening database. One additional
parameter, the yield, is also employed as the percentage of true hits retrieved by the virtual
screening method:
(5)
Cluster analysis of binding profiles
To closely evaluate the key receptor/ligand interaction patterns, we employed the LigX
module14 in MOE2007.09 to analyze the crystal structure of β2AR/carazolol complex and
the docking poses generated by Glide4.01. For each antagonist, the top-ranked docking pose
with the highest score was selected. Two major types of interactions that contribute to
protein/ligand binding affinities were considered, i.e. hydrogen bonds (donor or acceptor)
and non-bonded weak interactions. The score to assess the hydrogen bond is based on a
scale of 0 to 100% that indicates the probability of being a geometrically perfect hydrogen
bond while the score for non-bonded weak interaction is the pairwise distance between
residue and ligand atoms. In our studies, we took the default parameters in which 4.5
angstrom is the cutoff for weak interactions and 2.5 angstrom is the closest distance between
any residue/ligand atom pairs. The original score was normalized; thus, the values of the
modified scores were between 0 and 1, which is proportional to the interaction intensities.
To better visualize the binding patterns of docked poses for each theoretical models and
crystal structures, the LigX scores were transformed into heat maps and clustered using the
R statistical package48. We applied the hierarchical clustering with the Ward linkage
algorithm; thus, the patterns of interaction between 57 human β2AR antagonists and
residues in the active sites of three different structural models would be expected to be
similar if the respective clusters are similar.
In addition, we have exploited the Protein Ligand Interaction Fingerprints (PLIF, also
available in MOE2007.09) for the same purpose. PLIF can identify and score major protein/
ligand interactions, including hydrogen acceptor from sidechain, hydrogen donor to
sidechain, hydrogen acceptor from backbone, hydrogen donor to backbone, ionic attractions
and surface contacts. For each docking pose, the PLIF fingerprints ranging from 30 to 50
bits were generated. The relative frequencies of each identified fingerprint can be then used
to produce fingerprint significance chart, which is based on the hypothesis that ‘if the bit is
set, then the compound is active’.
Results and Discussion
Structural comparison of theoretical models and X-ray structures of β2AR
Prior to VS experiments, we analyzed the similarity between theoretical models and two X-
ray structures, i.e. 2RH1 and 1U19 deposited to the Protein Data Bank9. All theoretical
models used in this study are listed in Table I; each model was aligned against the X-ray
structures to evaluate relative definitions of transmembrane (TM) helices, their
conformations, and relative orientation. The X-ray structure of bovine rhodopsin (1U19) was
also included in addition to β2AR because the former had been used as a common template
for GPCRs homology modeling. In doing so, we were interested to explore if the failure to
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predict the structural conservation and/or divergence from the template structure may cause
poor VS results for the theoretical models.
Our initial efforts focused on evaluating the accuracy of TM helical boundaries as defined
by models vs. X-ray structures. For this purpose we have employed MOE 2007.09 software3
to annotate the secondary structural elements in the 3D structures. We found that the MOE
module assigned boundaries either at exact positions or only one amino acid apart to over
90% of the TM segments of 2RH1 and 1U19 in comparison with those in the PDB header.
Thus, the MOE software was deemed reliable in identifying the helical boundaries; the
results of applying MOE to the six theoretical models and two crystal structures (2RH1 and
1U19) are summarized in Figure 1a and Table II. From the alignment of the eight structures,
it can be seen that the apo models (AM1-AM3) perform better than the holo models (CM1-
CM3) in terms of accuracy of TM assignment. The location and length of the TM helixes for
all three AM models are consistently close to those in the rhodopsin structure (1U19), with
the only exception that TM6 and TM7 in the AM1 model are shorter than the corresponding
helices in the crystal structures. This observation can be easily rationalized since AM1 and
AM2 models are solely based on homology modeling whereas AM3 is a hybrid model
developed with a combination of both threading and ab initio methods. In all cases, the
crystal structures of bovine rhodopsin were used as a template for model building.
Furthermore, we have concluded that individual TM helixes were very close in terms of
helical length and relative orientation when compared to crystal structures of bovine
rhodopsin and human β2AR13. Thus, not surprisingly, given the methods used for model
building, the secondary structural elements for all three AM models were found to be
assigned very accurately as compared to their homologous experimental structures.
The accuracies of TM helix boundaries assignments for CM models were less satisfactory.
In general, seven TM helices in all three CM models were shorter than expected with the
largest disagreements located at TM1, TM4 and TM5 (cf. Figure 1a and Table II). The CM3
model gave the largest deviation in terms of the percentage of correctly defined TM helical
boundaries. Moreover, it had the shortest lengths for individual TM helices. For instance, it
was eight residues shorter for TM1, fourteen for TM3 and eleven for both TM5 and TM6 in
comparison with the β2AR crystal structure. One possible explanation is that all three CMs
are de novo models, generated without any template structure. Both the Lybrand (CM1, 2)
and the Goddard (CM3, 4) groups employed the standard alpha helix as a starting point and
calculated the intrinsic tilt/kink and relative orientation of the TM helical bundle purely
based on the physical considerations. If the rhodopsin structure is not employed as a
reference, the secondary structure assignments could be affected by many factors, such as
the type of phospholipid used in the MD simulations employed as part of model refinement
in studies by the Goddard group22, 54.
It should be noted that the engineered modification of the wild type protein using a segment
of T4 lysozyme to replace most residues of IL3 introduced an artifact in the crystal structure
(2RH1) of human β2AR. This modification led to altering the boundaries of IL3, thus
affecting the correct locations of both the TM5 terminus and the start of the TM6. The
accurate definition of these two boundaries is less important in the comparison of structural
similarities between theoretical models and the crystal structures. However, the accuracy of
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predicting the TM4 terminus and the beginning of TM5 is critical considering the functional
roles of EL2 in both rhodopsin and human β2AR6, 55. As can be seen from Figure 1a and
Table II among the three AM models, AM3 has the highest accuracy (one residue error) for
the segment between TM4 and TM5 (EL2) followed by AM2 and AM1. CM3 model is
comparable to AM2 while CM1 and CM2 had much larger errors with respect to TM helix
assignments.
The seven TM helices of each theoretical model were superimposed onto respective helices
of β2AR as well as the rhodopsin structure, and the backbone pairwise RMSD of individual
respective TM helices was calculated (Figures 1b, 1c and Table II). As expected, the
homology models (AMs) are generally more similar to the rhodopsin structure than to the
β2AR structure. The RMSDs of most helices in AM1-3 range from 0.30 Ǻ to 1.00 Ǻ as
compared to bovine rhodopsin where the RMSDs are as big as 1.60 Ǻ to 3.80 Ǻ when
aligned against the human β2AR. For the whole TMs bundle, the RMSDs are 1.15 Ǻ to 1.88
Ǻ with respect to rhodopsin and 2.25 Ǻ to 3.19 Ǻ with respect to β2AR. In comparison, the
de novo models (CMs) deviate more significantly from both crystal structures. The RMSDs
of most helixes in CM1/CM2 are in the same range of 2.00 Ǻ - 5.50 Ǻ when aligned against
both rhodopsin and β2AR. For CM3, the RMSD increases to 2.60 Ǻ and 7.00 Ǻ,
respectively. Similarly, the RMSDs of TMs bundle for CM1 are 3.20 Ǻ when aligned
against the rhodopsin and 3.59 Ǻ for β2AR. For CM3, the corresponding RMSDs are 3.83
Ǻ and 4.41 Ǻ (cf. Table II).
Consistently, the AMs models were observed to be aligned well to the rhodopsin structure
(cf. AM2 in Figure 1b as an illustrative example). They deviated from the β2AR structure
with the noticeable shifts for TM1, TM3 and TM5, although the secondary structure
assignment for these regions was relatively accurate. The large RMSD differences for these
three TMHs were obviously due to the differences between rhodopsin and β2AR crystal
structures (7TMs backbone RMSD of 2RH1 vs. 1U19 is 1.85 Å). It was indeed reported in
the original publication on β2AR crystal structure13 that there is a noticeable shift in TM1 of
β2AR relative to bovine rhodopsin, primarily at the extracellular portion which tilts away
from the TM bundle compared to bovine rhodopsin13, 51. The long N-terminal fragment
could not be observed in both crystal structures, but it could cause large flexibility/variation
in the assignment of TM1 boundaries, especially in the upper helical region. TM5 has a
proline-induced kink at conserved positions along the transmembrane segments, which is
believed to be responsible for the structural rearrangements required for the GPCRs
activation32, 36, 39, 58. The subtle difference in the activation status of the current β2AR
structure (2RH1, bound to an inverse agonist carazolol) may lead to the structural
diversification at the kink region, in terms of the amplitude of motion and rotation degree.
Notably TM3 and TM5 constitute half of the binding pockets for the co-crystallized
carazolol13 (Figure 1b).
Unlike AM models, three CMs deviate from both bovine rhodopsin and β2AR in a similar
way (cf. CM1 in Figure 1c as the representative case). A large discrepancy can be found at
TM1, 4, 6 and 7 for CM1/CM2 and TM1, 3, 5 and 6 for CM3. Here the similar reasoning
used in the analysis of AMs can be applied to TM1 because the N-terminal fragment was not
considered as part of model building and optimization. Interestingly, the RMSD of CM1’s
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TM4 is as large as 5.00 Ǻ with respect to rhodopsin and 5.21 Ǻ when aligned against
β2AR. It is surprising since TM4 seems the easiest one to model. Among all seven TMs,
TM4 is the shortest and the most orthogonal to the plane of the phospholipid membrane.
This observation indicates the limitation of computational protocols employed in developing
the CM models in their ability to reproduce the conformation of this ‘anchor’ helix in the
TM bundle. For TM5, 6 and 7, one of the common shared features is the proline-induced
kink. The comparisons between β2AR models and the crystal structures highlight the
difficulty associated with the accurate modeling of this unique structural feature of GPCRs.
Comparison of VS performance for theoretical models and X-ray structures of β2AR
Figure 2 shows the enrichment factor plot (a,c,e) and ROC curves (b,d,f) of 57 known β2AR
antagonists against decoys by three docking methods. The yield plot is shown in since it
essentially delivers the same information as the ROC curves. The detailed statistical
parameters characterizing the VS performance, such as the maximum EF (EFmax), ROC
AUC and the recently proposed Boltzmann-Enhanced Discrimination of ROC
(BEDROC)15, 56, are summarized in Table III. All four holo models as well as the β2AR
structure were used in the VS study. Because of the poor performance of the apo models in
general during virtual screening, we only showed the data for the relatively better ones
(AM1 and AM3) to represent the AMs group. In many cases, such as AM3 in Figures 2d
and 2f, the ROC curve is close to the random expectation (the diagonal line). It is
understandable because the side chain rotamers of binding pocket residues in the AM
models had not been optimized in the way it was done for holo models.
Among all four CMs models, those from the Lybrand group (CM1, CM2) achieved better
enrichment than the models from the Goddard group (CM3, CM4). In most cases, the CM2
model yielded comparable results to the β2AR crystal structure. In the screening by
Glide4.01, CM2 model gave higher EF at the very early phase (0% - 2% of ranked database,
cf. Figure 2a and Table III). After that, it remained up to one unit lower than the crystal
structure until converging with the latter at the 22% of ranked database. In terms of ROC
AUC, CM2 reached the value of 0.86, close to AUC of 0.88 for the crystal structure. Based
on the BEDROC metric, CM2 was similar to 2RH1 when α was small (α=20) while
showing better performance when α was large (α=53.6 or 100). We note that Glide4.01 gave
better VS results in this study compared to AutoDock4.0 and eHiTS6.2. Thus, we placed
more emphasis on the screening data/docking poses generated by Glide4.01. Nevertheless,
the results obtained with both AutoDock4.0 and eHiTS6.2 also highlighted the impressive
performance of CM2. As demonstrated by both types of plots in Figures 2c-f and most
criteria in Table III, the CM2 afforded VS results superior to the crystal structure when
using these two docking programs. Therefore, practically speaking, these results suggest that
the use of crystal structure is not advantageous in terms of VS performance when the scoring
function is not highly accurate. On the other hand, it reflects on the extreme sensitivity of
the docking approaches to small structural variations. As mentioned above, CM3 and CM4
had poorer performance than CM1 and CM2 but were comparable to AM1 and AM3 models
in this case (cf. Table III).
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The crystal structure of β2AR represents an inactive state of the receptor because it is bound
to the inverse agonist, carazolol13, 38. Thus, it may be considered unfair to compare the
crystal structure of β2AR with theoretical models as applied to agonist screening, especially
when the models were created to capture known data on agonists. However, for comparison
purposes, we did explore the possible utility of 2RH1 for screening for agonists. The
screening results are summarized in Figures 3 and Table IV. As expected, the CM2 model
showed the best performance to enrich for thirteen β2AR agonists. With Glide4.01 method,
the CM2 model could recover 100% of seed agonists at the 15% of ranked databases and its
maximum EF could be as high as 36.09. Thus, it excelled over 2RH1 greatly in terms of
these two parameters of VS performance. Taking into account the data for the antagonist
virtual screening, we shall conclude that CM2 model demonstrated remarkable performance
as a model of choice for virtual screening for both agonists and antagonists.
Figure 4, Table V and Table VI showed the results of virtual screening for antagonists and
agonists with decoys sets II and III. We observed that the relative performance between
crystal structures and theoretical models with new sets is similar to that observed in our
previous experiments, although the absolute performance of each protein model varied by
the choice of decoy sets. Notably the CM2 model was consistently ranked comparable to
three experimental structures to enrich fifty-seven β2AR antagonists (cf. Figure 4 and Table
V). And remarkably it outperformance structures 2RH1 and 3D4S for thirteen β2AR
agonists on most aspects of screening, and is comparable to the structure of 3P0G at the late
phase of screening (> 25% db, cf. Figure 4 and Table VI). Thus we believe that the
conclusions we drew from the decoys set I are valid and expandable to other screening
libraries, thus appear to be general.
The possible explanation of the better performance of CM1/CM2 models is that Lybrand et
al exploited many site-directed mutagenesis data during the model optimization24, 35. The
important receptor/ligand interactions had been turned into distance restraints that were
applied explicitly to specific atoms of both the receptor and its ligands during molecular
dynamics simulations24. In comparison, CM3 and CM4 models from Goddard et al did not
employ such information22, 54; their models were built by optimizing the target/ligand
interaction using physical force field. Obviously, the differences in the type of data utilized
for theoretical model building and optimization can largely affect the accuracy of binding
pocket modeling, and consequently, the model performance in virtual screening
experiments. In order to evaluate the similarity between binding pockets of individual
models, we superimposed Cα atoms of key residues inside the pocket with their counterparts
in 2RH1. The binding pocket was defined by residues found within 4 Å of the co-
crystallized carazolol. Carazolol was merged into the binding sites of all models as defined
by the alignment. As shown in Figure 5 (A-H), the CM2 binding pocket (Figure 5B) is most
similar to that of 2RH1 with respect to both the ligand pose and the position of residues
interacting with the ligand. The RMSD for its Cα atoms was 2.40 Ǻ while the one for CM1
was 2.33 Ǻ (cf. Table II). These two models also reproduced the contacts of carazolol with
residues Ser2035.42, Asn3127.39 and Phe193 . For three AMs models, the RMSDs ranged
from 3.39 Ǻ to 3.71 Ǻ. CM3 and CM4 models had the largest deviation (RMSD = 5.64 Ǻ),
as can also be seen in Figures 5C and 5D.
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Furthermore, the close inspection of the top-ranked docking poses of all seed antagonists
showed that the interactions between the antagonists and the binding site of the CM2 model
were largely in agreement with the site-directed mutagenesis data. The protonated nitrogen
in most β2AR antagonists formed salt bridges with ASP1133.32 and Asn3127.39; the amide
hydroxyl group formed hydrogen bonds with Ser2035.42, Ser2045.43 or Ser2075.46. Another
important interaction was formed between antagonists and Phe193 of EL2, i.e., the residue
that was also found to interact with carazolol within the crystallographic structure of
β2AR13, 24, 51. It should be pointed out that CM2/CM1 models include both extracellular
and intracellular loops, whereas CM3/CM4 and AM1 models did not incorporate these
regions22, 51.
To elucidate the molecular basis for dissimilar virtual screening performance of different
CM2 and CM3 models in comparison with 2RH1 we have conducted the cluster analysis of
the binding profiles of all 57 antagonists docked to the respective binding sites. Binding
profiles reflected the strengths of interaction between antagonists and active site residues.
Importantly, there were significant differences in the weak interaction patterns of CM2
(Figure 6b) and CM3 (Figure 6c) in comparison with 2RH1 (Figure 6a). The major clusters
formed by CM2 in the region of conserved residues matched well to those found in 2RH1,
suggesting a critical role of weak interactions between binding site and antagonists. In
comparison, clusters formed by CM3 were scarce and many key interactions were missing,
especially for residues Trp2866.48, Phe2896.51, Phe2906.52 and Asn2936.55 of the binding
pocket. This analysis indicates that the binding pocket of CM2 was well-organized and
similar to that of 2RH1 whereas the CM3 binding pocket was formed by somewhat different
residues, with the key residues found in the binding site of the X-ray structure were
inaccessible to the bound antagonists. The cluster profile of hydrogen bonding pattern was
less informative as some prominent patterns at 2RH1 such as the ones with Asn3127.39 were
absent at both CM2 and CM3. Notably, Ser2045.43 and Ser2075.46 of CM2 were found to be
hydrogen bonded to ca. 15 antagonists, but the same pattern was not observed with either
CM3 or 2RH1.
During the course of our studies, Kobilka et al. experimentally characterized two new
structures of β2AR, one in a nanobody-stabilized active state and another in complex with
an irreversible agonist. In comparison with the structures of inactive state of β2AR, the
agonist-binding pockets showed fairly subtle changes, with the differences at the hydrogen
bonding contacts with Ser2035.42 and Ser2075.46 residues49, 52. To determine whether these
minor changes will increase the receptor’s selectivity toward agonists, we carried out
structure-based virtual screening studies using the nanobody-stabilized structure (PDB ID:
3P0G), and compared its performances with the inactive state structure as well as our
collection of theoretical models. As expected, the structure of the active state showed better
performances than its counterparts of the inactive state in enriching for thirteen agonists but
less effective in enriching for fifty-seven antagonists (Figures 2a-b, 3a-b). With Glide4.01
docking protocol, the active state structure could recover 100% of seed agonists at the 25%
of ranked databases with the maximum EF as high as 30.69. On the other hand, the active
state model of CM2 showed comparable performances to the 3P0G structure in terms of EF
and AUC metrics (cf. Table III and Table IV). As mentioned above, the de novo model of
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CM2 had captured the critical agonist-protein interaction at Ser2075.46 (cf. Figure 5G). This
piece of evidence provides another illustration that the properly optimized theoretical
models can provide a sensible and accurate description of the binding pocket of the active
state structure, and therefore they can be employed reliably for structure-based virtual
screening of β2AR agonists.
To summarize our observations, we established that theoretical models of GPCRs built by
knowledge-based approaches can achieve similar if not better VS performance as
experimental structures from X-ray crystallographic studies. This somewhat surprising
observation is reassuring with respect to using carefully developed theoretical models of
protein structures for SBDD.
Conclusions
In this study we have addressed the long-standing debate about the structural accuracy and
applicability of theoretical models vs. X-ray structures of GPCRs for SBDD. We have
carried out a systematic study on a large collection of historical human β2AR theoretical
models and evaluated their structural accuracies and screening performances in comparison
with recent agonist-bound and antagonist-bound crystal structures. We have shown that
there exists a discrepancy between global structural accuracies of β2AR theoretical models
and their screening performances. In general, β2AR theoretical models differ largely from
the crystal structure in terms of TMHs definition and global packing while many can
achieve the same performance in virtual screening and as demonstrated elsewhere16, pose
predictions. Our analysis indicates that the binding pockets of models showing the best
performance are well-organized and they also align well to active sites in the crystal
structures. The key interactions of residues in the active site with the bound antagonists were
found to be preserved in models that were built and refined taking into account the site-
directed mutagenesis and other experimental data (i.e. the CM1 and CM2 models). Our
results emphasize that knowledge-based approaches result in structural models that can
achieve the same or even better performance in virtual screening as those built with X-ray
crystallographic data. Also, we must stress that our studies address very specific (i.e. β2AR
or GPCRs) and pragmatic question (i.e. virtual screening) concerning the use of protein
models vs. experimental structures for virtual screening. Our observations by no means
undermine the critical importance of experimental structures for understanding protein
structure-function relationships as well as the role that crystal structures serve as a critical
reference for evaluating the accuracy of predicted protein/ligand interactions.
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The structural similarity analysis of theoretical models in comparison with crystal structures.
(a) The secondary structure assignment for TM segments of six theoretical models and two
crystal structures (2RH1 and 1U19). The numbers and their corresponding structures are
coded by 1:2RH1, 2:AM1, 3:AM2, 4:AM3, 5:CM1, 6:CM2, 7:CM3, 8:1U19. The remaining
two models, i.e., AM4 and CM4, share similar backbone structures to CM3 with pairwise
RMSD of TMs less than 0.4 Ǻ. Therefore only CM3 is included in the sequence alignment
plot. The red bars indicate the helical structure elements identified by MOE. (b) The
structural superposition of the theoretical models AM2 (rendered in pink) to 2RH1 (rendered
in dark green) and 1U19 (rendered in blue). Note that the most structurally divergent TM
regions are indicated. (c) The structural superposition of the theoretical models CM1
(rendered in pink) to 2RH1 (rendered in dark green) and 1U19 (rendered in blue). Note that
the most structurally divergent TM regions are indicated as well.
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The docking performance of six theoretical models in comparison to three crystal structures
2RH1, 3D4S and 3P0G. The enrichment (a, c, e) and ROC curves (b, d, f) of fifty-seven
known β2AR antagonists with the decoys set I by three docking methods. The annotations
are (a, b) Glide4.01 (c, d) AutoDock4.0 and (e, f) eHiTS6.2.
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The enrichments and ROC curves of thirteen known β2AR agonists with the decoys set I
during the screening against six theoretical models and two crystal structures (2RH1 and
3P0G). The annotations are (a, b) Glide4.01 (c, d) AutoDock4.0 and (e, f) eHiTS6.2.
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The docking performance of six theoretical models in comparison to three crystal structures
2RH1, 3D4S and 3P0G with the decoys sets II and III. The enrichment (a) and ROC curves
(b) of fifty-seven known β2AR antagonists and the enrichment (c) and ROC curves (d) of
thirteen known β2AR agonists with the decoys set II. The enrichment (e) and ROC curves
(f) of fifty-seven known β2AR antagonists and the enrichment (g) and ROC curves (h) of
thirteen known β2AR agonists with the decoys set III.
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The comparison of the binding pockets of theoretical models versus the β2AR crystal
structures of inactive state (2RH1; A:CM1, B:CM2, C:CM3, D:CM4, E:AM1) and active
state (3P0G; F:2RH1, G:CM2, H:CM4). The active sites were superimposed by Ca atoms of
key binding site residues of 2RH1 (W3.28, D3.32, V3.33, V3.36, T3.38, F5.32, Y5.38,
S5.42, S5.43, S5.46, W6.48, F6.51, F6.52, N6.55, Y7.35, N7.39, Y7.43). The crystal
structures 2RH1 and 3P0G are colored in green and blue respectively, while the model
structures are colored in pink.
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The cluster analysis of the antagonists binding profile. (Upper panel, a-c) The comparison
of weak interaction profiles of fifty-seven antagonists of human β2AR with 2RH1 (a), CM2
(b) and CM3 (c). (Lower panel, d-f) The comparison of hydrogen bonding (HBond)
profiles of fifty-seven antagonists of human β2AR with 2RH1 (d), CM2 (e) and CM3 (f).
The weak and HBond interactions were identified/scored by LigX module in MOE2007.09
and marked as X.1 for HBond donors and X.2 for HBond acceptors. In the case that one
residue forms two HBonds to the ligand, the interactions were labeled as X(I).X or X(II).X,
in which the X(I).X had the better score. The upper block in each map contains the binding
pocket residues of 2RH1 while the lower block contains other interacting residues. Each
point in the maps represents the identified interactions and was shaded by their respective
scores, wherever darker indicates higher score and thus greater interaction strength. All the
points in the map had been reorganized using hierarchical clustering by interaction scores.
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The significance chart for PLIF fingerprints generated from docking poses against (a) β2AR
crystal structure (2RH1), (b) CM2 model and (c) CM3 model. The higher the bar (individual
fingerprint bit) is, more frequently this type of interaction occurs in the dataset and of higher
probability it contributes to the activities. The shade of the color indicates the significance of
the particular bit to the actives, which is based on the hypothesis that ‘if the bit is set, then
the compound is active’. The residues are randomly colored and several bars of the same
residue indicate that they have different types of contacts.
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Table I
The synonym of eight human β2AR theoretical models employed in this study.
Apo model Source Holo model Source
AM1 By G. Vriend, a homology model(7) based on the
crystal structure of bovine rhodopsin
CM1 By T. Lybrand, a de novo model(1, 5) bound by
aminoflisopolol (β2AR antagonist)
AM2 By A. Sali, a homology model(6) based on the
crystal structure of bovine rhodopsin
CM2 By T. Lybrand, a de novo model(1, 5) bound by TA2005
(β2AR agonist)
AM3 By J. Skolnick, a hybrid model(2) combined
threading and ab initio methods
CM3 By W. Goddard, a de novo model(3, 4) bound by
butoxamine (β2AR antagonist)
AM4 By W. Goddard, a de novo model(3) based on first
principles methods
CM4 By W. Goddard, a de novo model(3, 4) bound by
salbutamol (β2AR agonist)





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Proteins. Author manuscript; available in PMC 2014 August 15.
